More than 70 tyrosine kinase (TK) fusion genes have been identified in myeloid neoplasms as a consequence of reciprocal translocations or other genomic rearrangements. These TK fusions are generally primary drivers of myeloproliferation and important therapeutic targets, as well as being major criteria for the diagnosis of specific disorders. For example, chronic myeloid leukemia is defined by the presence of BCR-ABL1, and myeloid/lymphoid neoplasms with eosinophilia are defined by fusions involving PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. 1 Other TK fusions have been described in patients with various subtypes of myeloproliferative neoplasms (MPN) or myelodysplastic syndrome/MPN. Most of these individuals have pronounced eosinophilia, 2 but occasional cases have other phenotypes, such as polycythemia vera (PV) or systemic mastocytosis. 2, 3 Apart from FIP1L1-PDGFRA, which is formed by a small deletion at 4q12, 4 TK fusions are almost always associated with visible karyotypic abnormalities. Despite their apparent prominence in the literature, TK fusions are in fact uncommon and the pathogenesis of the majority of MPN with eosinophilia (MPN-eo) remains unexplained. Some TK fusion-negative cases test positive for KIT D816V or JAK2 V617F, whereas others are positive for mutations in a range of genes associated with myeloid disorders, such as TET2, ASXL1, EZH2 and SETBP1. [5] [6] [7] We hypothesized that hitherto undetected cryptic TK fusion genes may drive MPN-eo, as well as other disorders, such as JAK2-unmutated PV.
We used RNAseq to search for TK fusion genes in cases with MPN-eo or hypereosinophilia of unknown significance with a normal karyotype (n = 14), PV with low or normal erythropoietin levels that tested negative for MPN phenotype driver mutations (n = 6) and cell lines that were derived from MPN or myelodysplastic syndrome patients that had transformed to acute myeloid leukemia (F-36P, ELF-153, FKH-1, GDM-1, SKK-1, SKM-1). RNA extraction, polyA + RNA-Seq library preparation, stranded RNAseq protocol and 100 bp paired-end sequencing was performed with multiplexing for a minimum of 75 million reads/sample using a HiSeq 2000 (Illumina, Little Chesterford, UK). Bowtie and TopHat-Fusion were used to align reads, resolve splice junctions, identify and filter potential TK fusions as previously described. 8 Confirmation and screening of fusions were performed by reverse transcriptase-PCR and Sanger sequencing ( Supplementary Table 1 ).
Of the 20 patient samples, 2 novel TK fusions were identified. Inframe DIAPH1-PDGFRB and ZMYM2-FLT3 fusion mRNAs (Figure 1 ; Supplementary Figures 1 and 2) were found in single patients with MPN-eo. None of the cases were positive for TNIP1-PDGFRB, a recently described cryptic fusion in MPN-eo. 9 Unusually, the fusion breakpoints in our cases fell within exons of both the partner and TK genes. No TK fusions were detected in the PV cases, but the FKH-1 and SKK-1 cell lines were positive for ETV6-ABL1 and ETV6-NTRK3, respectively (Supplementary Figure 3 ). Although these fusions have been described previously, neither line was known to be positive and the presence of these fusions was not suspected on the basis of the karyotype. 10, 11 DIAPH1 and PDGFRB are located 8.5 Mb apart at 5q31.3 and 5q32, respectively. They are both oriented from telomere to centromere and thus the fusion presumably arose as a consequence of a tandem duplication or a translocation t(5;5)(q31.3;q32), both of which would be difficult to detect by routine cytogenetics. The affected patient, a 37-year-old male, was diagnosed with an MPN-eo and contemporaneous T-cell lymphoblastic lymphoma, most likely representing extramedullary lymphoid blast phase. 12 The karyotype was normal. The patient received intensive chemotherapy and achieved complete hematological remission with disappearance of the lymphadenopathy. Two weeks later, he developed leukocytosis (119 × 10 9 /l) with significant eosinophilia (21 × 10 9 /l), hepatosplenomegaly but with no recurrence of lymphadenopathy. Consolidation intensive chemotherapy treatment was started without response. Molecular analyses revealed overexpression of PDGFRB 13 and the DIAPH1-PDGFRB fusion was subsequently identified by RNAseq analysis. He received imatinib 100 mg/day and achieved complete hematological remission within 4 weeks but died owing to a rapidly progressive neurodegenerative disorder at month 27 while still in complete remission. To test whether DIAPH1-PDGFRB is a recurrent abnormality, we screened 50 Accepted article preview online 28 July 2017; advance online publication, 15 August 2017 additional cases with MPN-eo by reverse transcriptase-PCR but did not identify any further positive cases.
ZMYM2 and FLT3 are both located at 13q12 and are in opposite orientations. ZMYM2-FLT3 is thus predicted to arise as a consequence of an 8 Mb inversion ( Supplementary Figure 3) . ZMYM2 is the fourth gene reported to fuse to FLT3 in myeloid neoplasms 2 but the first FLT3 fusion that is cytogenetically cryptic. We screened 105 additional cases with MPN-eo, hypereosinophilia of unknown significance or other atypical MPN by reverse transcriptase-PCR. One additional positive case was detected, with similar but not identical breakpoints to the initial case ( Figure 1 ). PCR analysis of genomic DNA for the second case (DNA was not available from Case 1) revealed that the cDNA and genomic breakpoints were identical, indicating the formation of a fusion exon by the inversion. We note that a third case with ZMYM2-FLT3 has been reported recently in a patient with BCR-ABL1-like acute lymphoblastic leukemia. 14 Both cases with ZMYM2-FLT3 had MPN-eo. Case 1, a 48-year-old female, presented with leukocytosis (30 × 10 9 /l), eosinophilia (2 × 10 9 /l, elevated serum tryptase (37 μg/l), splenomegaly and a hypercellular bone marrow with increased numbers of loosely scattered mast cells. Cytogenetics was normal; FIP1L1-PDGFRA, KIT D816V and JAK2 V617F were all negative; and no relevant mutations were identified by myeloid panel analysis (28 genes). After 10 months, she progressed to myeloid blast phase. Because the disease was resistant to acute myeloid leukemia induction chemotherapy, an allogeneic peripheral blood stem cell transplant was performed from an unrelated donor 13 months after diagnosis. She died 6 months later from chronic graft-versushost disease and septic shock; the ZMYM2-FLT3 fusion was identified postmortem.
Case 2, a 47-year-old male, presented with eosinophilia (4.7 × 10 9 /l), elevated serum tryptase (42 μg/l) and a hypercellular bone marrow. Cytogenetics was normal and FIP1L1-PDGFRA, KIT D816V and JAK2 V617F were all negative. There was no response to steroids or hydroxyurea. Following the finding of ZMYM2-FLT3 positivity, treatment with sunitinib off-label at 50 mg/day was commenced. Blood counts started to improve from day 4 and normalized after 3 weeks. During a pause of 3 weeks due to pulmonary infection, leukocytes/eosinophils rapidly increased but normalized again within weeks after restart of sunitinib, initially at a dose of 25 mg/day and then subsequently 35 mg/day. The patient has been maintained on sunitinib for 10 months (since restart) and remains in complete hematological remission ( Figure 2 ).
In conclusion, we have found that ZMYM2-FLT3 and DIAPH1-PDGFRB fusion genes are novel, cytogenetically cryptic and therapeutically targetable abnormalities in MPN-eo and are thus reminiscent of FIP1L1-PDGFRA-positive myeloid neoplasms. Owing to their extensive diversity and clinical importance, we believe that genome-wide or targeted RNAseq is rapidly becoming the method of choice to detect rare TK fusions. ) and hydroxyl radicals (OH − ) that facilitate cell processes such as homeostasis and antimicrobial responses. 1 Several studies have indicated a relationship between ROS and chronic lymphocytic leukemia (CLL) cell survival. [2] [3] [4] Upon crosslinking and activation of the B-cell receptor (BCR) on the surface of B cells, particularly in B2 B cells, NOX2 produces ROS that subsequently inhibits tyrosine phosphatases. 5 This inhibition then promotes BCR signal amplification. 5 Unlike B2 B cells, CD5 + B1a B cells, which are already detected during early fetal development and which reside primarily in the peritoneal cavity (PerC), are autoreactive and spontaneously secrete IgM. 6 These B1a B cells show distinct characteristics compared with that of B2 B cells in response to BCR ligation. 6 The human equivalent of CD5 + B1a B cells in mice are thought to be the origin of CLL cells. 7 Cell-autonomous BCR ligation and low-affinity autoantigens, such as phosphatidylcholine (PtC) and Sm, drive CLL development. 8 As there are many similarities with human CLL, murine CLL cells provide useful tools for in vitro and in vivo study of the biology of the disease and for testing therapeutic interventions. Monoclonal antibody treatments, for example, with anti-CD20 or anti-SLAMF6, can efficiently remove CLL cells in peripheral blood and lymphoid organs, in part by antibody-dependent cell-mediated cytotoxicity (ADCC). 9,10 However, these reagents are not effective in removing CLL cells in PerC, 9, 10 even though coating of B cells with anti-CD20 antibody and duration of binding to the surface of B cells residing in the PerC and in blood or lymphoid organs is similar. 9 This suggests that there could be a mechanism provided by the microenvironment that offers protection to B cells in the PerC. Given the importance of ROS in tumor microenvironments, we hypothesized that ROS plays a niche-specific role in CLL. To test this idea, we used severe combined immunodeficient (SCID) mice transplanted with murine TCL1-192 leukemic cells, clonal VH11/Vk14 BCR and reactive with PtC, derived from TCL1-bearing mice. 11 Expansion of TCL1-192 cells in SCID mice results in aggressive disease progression, similar to observations in CLL patients with unmutated IGHV.
First, we determined extracellular O 2 − levels in TCL1-192 cells by luminol-based chemiluminescent reagent, as an indicator of basal ROS production. Cells are freshly isolated and processed from Accepted article preview online 28 July 2017; advance online publication, 15 August 2017
